Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion type Assertion NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_head.
- NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion description "[Monoclonal antibodies (trastuzumab, gefitinib, erlotinib and bevacizumab) targeting tissue markers and involved in tumor growth and metastasization (EGFR, C-erbB-2, VEGF) have been developed; they showed therapeutical single agent activity as well as potent synergy with chemotherapy agents in metastatic cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_provenance.
- NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion evidence source_evidence_literature NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_provenance.
- NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion SIO_000772 16368559 NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_provenance.
- NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion wasDerivedFrom befree-20140225 NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_provenance.
- NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_assertion wasGeneratedBy ECO_0000203 NP184908.RAc8IOy3XdwrMS7yhI8-dJr8_FIqAHQv9DGnbEFYC5QX8130_provenance.